Avalon Pharma renews SAR 50M credit facilities with Alinma Bank
- Source
- Argaam - Company Disclosures
- Source link
- https://www.argaam.com/en/article/articledetail/id/1930701
- Published
- 2026-08-20 09:20:00
- Discovered by ProcIntel
- 2026-08-20 16:28:24
- Category
- Supplier Risk
- Geography
- Saudi Arabia, UAE
- Organisations
- —
- Review status
- Pending
- Record type
- REAL
Summary
<p ><img src="https://argaamplus.s3.amazonaws.com/ce6cd0fc-562a-4bc7-bb47-9a988b13a218.png" ></p> <p class="ckeCaption" >Logo ofMiddle East Pharmaceutical Industries Co. (Avalon Pharma)</p> <hr> <p >Middle East Pharmaceutical Industries Co. (<a href="http://www.argaam.com/en/tadawul/tasi/avalon-pharma" target="_blank">Avalon Pharma</a>) said it renewed Shariah-compliant credit facilities worth SAR 50 million with <a href="http://www.argaam.com/en/tadawul/tasi/alinma" target="_blank">Alinma Bank</a>.</p> <p ></p> <p >In a statement to <strong>Tadawul</strong>, the company said the one-year facilities were renewed on Aug. 19.</p> <p ></p> <p >The facilities will support working capital and capital expenditure.</p> <p ></p> <p >There are no related parties to the deal, the statement added.</p>
Procurement Relevance Gate
- geographic_exposure (weight 8) — matched on "2 linked geographies"
Initial Signal Assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically-computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Not Assessed — this Signal did not pass the Procurement Relevance Gate, or is fictional/excluded test data.